文章摘要
寒喘祖帕颗粒联合沙美特罗替卡松粉吸入剂对支气管哮喘缓解期患儿血清CD4+/CD8+水平的影响
Effect of Hanchuan Zupa Granule and Salmeterol Ticassone Inhalation on Serum CD4+/CD8+ Level in Children with Bronchial Asthma in Remission Stage
投稿时间：2019-06-20  修订日期：2020-01-10
DOI：
中文关键词: [关键词] 寒喘祖帕颗粒  沙美特罗替卡松粉吸入剂  支气管哮喘缓解期  CD4+/CD8+
英文关键词: [Key words]: Hanchuan Zupa Granule  Salmeterol and Ticasone Powder Inhalation  Bronchial Asthma Remission Period  CD4+/CD8+
基金项目:
作者单位邮编
尹彬* 内江市妇幼保健院 641000
邱静 内江市妇幼保健院 
邓德明 内江市妇幼保健院 
唐红 内江市妇幼保健院 
刘汉玲 内江市妇幼保健院 
肖盛蕾 内江市妇幼保健院 
摘要点击次数: 222
全文下载次数: 0
中文摘要:
      [摘要] 目的 分析寒喘祖帕颗粒联合沙美特罗替卡松粉吸入剂对支气管哮喘缓解期患儿血清CD4+/CD8+水平的影响。方法 选取2016年8月～2018年7月我院收治的78例支气管哮喘缓解期患儿，简单随机化分组，各39例，对照组给予沙美特罗替卡松粉吸入剂，观察组加用寒喘祖帕颗粒，）比较两组肺功能指标[用力肺活量（FVC）、最大呼气流量（PEF）、一秒用力呼气容积（FEV1）、用力呼气量占肺活量百分比（FEV1/FVC）水平]、炎症指标[中性粒细胞（PMN）、嗜酸性粒细胞（EOS）、单核细胞趋化蛋白-4（MCP-4）、白细胞介素-4（IL-4）、肿瘤坏死因子-α（TNF-α）]、免疫功能指标（CD3+、CD4+/CD8+）水平、Toll样受体4(TLR4)、核转录因子-kappa B(NF-κB) mRNA表达、不良反应发生率，随访半年，统计两组哮喘急性发作率。结果 观察组治疗后FVC、PEF、FEV1、FEV1/FVC高于对照组（P＜0.05）；观察组治疗后血清MCP-4、PMN、EOS、IL-4、TNF-α低于对照组（P＜0.05）；观察组治疗后血清CD3+、CD4+/CD8+水平高于对照组（P＜0.05）；观察组治疗后TLR4、NF-κB mRNA低于对照组（P＜0.05）；观察组不良反应发生率（5.13%）与对照组（7.69%）相比，差异无统计学意义（P＞0.05）；随访半年，观察组无哮喘急性，哮喘急性发作率低于对照组（17.95%）（P＜0.05）。结论 寒喘祖帕颗粒联合沙美特罗替卡松粉吸入剂治疗支气管哮喘缓解期，可提高患儿肺功能、免疫功能，预防哮喘急性发作，并改善患儿气道炎症反应，安全可靠。
英文摘要:
      [Abstract] Objective: To analyze the effect of Hanchuan Zupa Granule combined with salmeterol and fluticasone powder inhalation on serum CD4+/CD8+ levels in children with bronchial asthma in remission stage. Methods: From August 2016 to July 2018, 78 children with bronchial asthma in remission period were randomized. The control group was given salmeterol and fluticasone powder inhalation, while the observation group was given cold asthma Zupa granule. The lung function indexes [forced vital capacity (FVC), maximum expiratory flow (PEF), forced expiratory volume (FEV1), forced expiratory volume (FEV1), Percentage of vital capacity (FEV1/FVC) level], inflammatory markers [PMN, EOS, monocyte chemoattractant protein-4 (MCP-4), interleukin-4 (IL-4), tumor necrosis factor-alpha (TNF-alpha)], immune function indicators (CD3+, CD4+/CD8+), Toll-like receptor-4 (TLR4), nuclear transcription factor-kappa (NF-kB) expression, the incidence of adverse reactions were compared between the two groups. Followed-up for half a year, the acute attack rate of asthma in the two groups was counted. Results: After treatment, FVC, PEF, FEV1, FEV1/FVC in the observation group were higher than that in the control group (P < 0.05); serum MCP-4, PMN, EOS, IL-4 and TNF-alpha in the observation group were lower than that in the control group (P < 0.05); serum CD3+, CD4+/CD8+ levels in the observation group were higher than that in the control group (P < 0.05); TLR4 and NF-kappa B mRNA in the observation group were lower than that in the control group (P < 0.05); The rate (5.13%) was not significantly different from that of the control group (7.69%) (P > 0.05). After six months of follow-up, there was no acute asthma in the observation group, and the acute attack rate of asthma was lower than that in the control group (17.95%) (P < 0.05). Conclusion: Hanchuan Zupa Granule combined with salmeterol and fluticasone powder inhalation can improve pulmonary function, immune function, prevent acute attack of asthma and improve airway inflammation in children with bronchial asthma in remission stage, which is safe and reliable.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭